Component-resolved diagnosis in hymenoptera allergy
Main Article Content
Keywords
Component resolved diagnosis, Allergy, Hymenoptera, Insect stings, Anaphylaxis, Vespula, Polistes, Apis, Cross-reactivity
Abstract
Component-resolved diagnosis based on the use of well-defined, properly characterised and purified natural and recombinant allergens constitutes a new approach in the diagnosis of venom allergy. Prospective readers may benefit from an up-to-date review on the allergens. The best characterised venom is that of Apis mellifera, whose main allergens are phospholipase A2 (Api m1), hyaluronidase (Api m2) and melittin (Api m4). Additionally, in recent years, new allergens of Vespula vulgaris have been identified and include phospholipase A1 (Ves v1), hyaluronidase (Ves v2) and antigen 5 (Ves v5). Polistes species are becoming an increasing cause of allergy in Europe, although only few allergens have been identified in this venom. In this review, we evaluate the current knowledge about molecular diagnosis in hymenoptera venom allergy.
References
1. Pesek RD, Lockey RF. Treatment of Hymenoptera venom allergy: an update. Curr Opin Allergy Clin Immunol. 2014;14:340-8.
2. Ollert M, Blank S. Anaphylaxis to insect venom allergens: role of molecular diagnosis. Curr Allergy Asthma Rep. 2015;15:26.
3. Elberink JN, Dubois AE. Quality of life in insect venom allergic patients. Curr Opin Allergy Clin Immunol. 2003;3:287-93.
4. Alfaya T, Vega A, Domínguez-Noche C, Ruíz B, Marques L, Sánchez-Morillas L. Longitudinal validation of the Spanish versión of the health-related quality of life questionnaire for hymenoptera venom allergy (HRQLHA). J Invest Allergol Clin Immunol. 2015;25:426-30.
5. Armisén M, Guspi R, Alfaya T, Crus S, Fernández S, DomínguezNoche C, et al. Cross-sectional validation of a quality of life questionnaire in Spanish for patients allergic to hymenoptera venom. J Investig Allergol Clin Immunol. 2015;25:176-82.
6. Sastre J. Molecular diagnosis in allergy. Clin Exp Allergy. 2010;40:1442-60.
7. Golden DB. Insect sting anaphylaxis. Immunol Allergy Clin North Am. 2007;27:261-72.
8. Müller U, Schmid-Grendelmeier P, Hausmann O, Helbling A. IgE to recombinant allergens Api m1, Ves v1 and Ves v5 distinguish double sensitization from crossreaction in venom allergy. Allergy. 2012;67:1069-73.
9. Pérez-Riverol A, Justo-Jacomini DL, Lima Zollner R, BrochettoBraga MR. Facing hymenoptera venom allergy: from natural to recombinant allergens. Toxins. 2015;7:2551-70.
10. Müller UR, Johansen N, Petersen AB, Fromberg-Nielsen J, Haeberli G. Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m1 and Ves v5. Allergy. 2009;64:543-8.
11. Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN. Diagnosis of hymenoptera venom allergy. Allergy. 2005;60: 1339-49.
12. Cifuentes L, Vosseler S, Blank S, Seismann H, Pennino D, Darsow U, et al. Identification of hymenoptera venom-allergic patients with negative specific IgE to venom extract by using recombinant allergens. J Allergy Clin Immunol. 2014;133: 909-10.
13. Marth K, Focke-Tejkl M, Lupinek C, Valenta R, Niederberger V. Allergen peptides, recombinant allergens and hypoallergens for allergen-specific immunotherapy. Curr Treat Options Allergy. 2014;1:91-106.
14. Monsalve RI, Vega A, Marques L, Miranda A, Fernández J, Soriano V, et al. Component-resolved diagnosis of vespid venom-allergic individuals: phospholipases and antigen 5s are necessary to identify Vespula or Polistes sensitization. Allergy. 2012;67:528-36.
15. Peiren N, Vanrobaeys F, de Graaf DC, Devreese B, Van Beeumen J, Jacobs FJ. The protein composition of honeybee venom reconsidered by a proteomic approach. Biochim Biophys Acta. 2005;1752:1-5.
16. Müller UR. Recombinant Hymenoptera venom allergens. Allergy. 2002;57:570-6.
17. Brown TC. Reactions to honeybee stings: an allergic prospective. Curr Opin Allergy Clin Immunol. 2013;13:365-71.
18. Spillner E, Blank S, Jakob T. Hymenoptera allergens: from venom to ‘‘venome’’. Front Immunol. 2014;5:77.
19. Sobotka AK, Franklin RM, Adkinson NF, Valentine M, Baer H, Lichtenstein LM. Allergy to insect stings. II. Phospholipase A: the major allergen in honeybee venom. J Allergy Clin Immunol. 1976;57:29-40.
20. Köhler J, Blank S, Müller S, Bantleon F, Frick M, Huss-Marp J, et al. Component resolution reveals additional major allergens in patients with honeybee venom allergy. J Allergy Clin Immunol. 2014;133:1383-9, 1389.e1-6.
21. Müller U. Insect sting allergy clinical: clinical picture, diagnosis and treatment. Stuttgart, New York: Gustav Fis.; 1990.
22. Kuchler K, Gmachl M, Sippl MJ, Kreil G. Analysis of the cDNA for phospholipase A2 from honeybee venom glands. The deduced amino acid sequence reveals homology to the corresponding vertebrate enzymes. Eur J Biochem. 1989;184:249-54.
23. Müller UR, Dudler T, Schneider T, Crameri R, Fischer H, Skrbic D, et al. Type I skin reactivity to native and recombinant phospholipase A2 from honeybee venom is similar. J Allergy Clin Immunol. 1995;96:395-402.
24. Dudler T, Chen WQ, Wang S, Schneider T, Annand RR, Dempcy RO, et al. High-level expression in Escherichia coli and rapid purification of enzymatically active honey bee venom phospholipase A2. Biochim Biophys Acta. 1992;1165:201-10.
25. Sturm GJ, Hemmer W, Hawranek T, Lang R, Ollert M, Spillner E, et al. Detection of IgE to recombinant Api m 1 and rVes v 5 is valuable but not sufficient to distinguish bee from wasp venom allergy. J Allergy Clin Immunol. 2011;128:247-8.
26. Koroˇsec P, Silar M, Zidarn M, Koˇsnik M. Reply: to PMID 22277204. J Allergy Clin Immunol. 2012;130:818-9.
27. Jakob T, Köhler J, Blank S, Magnusson U, Huss-Marp J, Spillner E, et al. Comparable IgE reactivity to natural and recombinant Api m 1 in cross-reactive carbohydrate determinant-negative patients with bee venom allergy. J Allergy Clin Immunol. 2012;130:276-8, author reply 278-9.
28. Koroˇsec P, Ziberna ˇ K, ˇSilar M, Deˇzman M, Celesnik ˇ Smodiˇs N, Rijavec M, et al. Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy. Clin Exp Allergy. 2015;45:1579-89.
29. Ruiz B, Serrano P, Verdú M, Moreno C. Sensitization to Api m 1, Api m 2, and Api m 4: association with safety of bee venom immunotherapy. Ann Allergy Asthma Immunol. 2015;114: 350-2.
30. Schrautzer C, Bokanovic D, Hemmer W, Lang R, Hawranek T, Schwarz I, et al. Sensitivity and specificity of Hymenoptera allergen components depend on the diagnostic assay employed. J Allergy Clin Immunol. 2016;137:1603-5.
31. Soldatova LN, Crameri R, Gmachl M, Kemeny DM, Schmidt M, Weber M, et al. Superior biologic activity of the recombinant bee venom allergen hyaluronidase expressed in baculovirus infected insect cells as compared with Escherichia coli. J Allergy Clin Immunol. 1998;101:691-8.
32. King TP, Spangfort MD. Structure and biology of stinging insect venom allergens. Int Arch Allergy Immunol. 2000;123: 99-106.
33. Jin C, Focke M, Leonard R, Jarisch R, Altmann F, Hemmer W. Reassessing the role of hyaluronidase in yellow jacket venom allergy. J Allergy Clin Immunol. 2010;125, 184-90.e1.
34. Kemeny DM, Dalton N, Lawrence AJ, Pearce FL, Vernon CA. The purification and characterisation of hyaluronidase from the venom of the honey bee, Apis mellifera. Eur J Biochem. 1984;139:217-23.
35. Gmachl M, Kreil G. Bee venom hyaluronidase is homologous to a membrane protein of mammalian sperm. Proc Natl Acad Sci U S A. 1993;90:3569-73.
36. Schröder E, Lübke K, Lehmann M, Beetz I. Haemolytic activity and action on the surface tension of aqueous solutions of synthetic melittins and their derivatives. Experientia. 1971;27:764-5.
37. Paull BR, Yunginger JW, Gleich GJ, Melittin: an allergen of honeybee venom. J Allergy Clin Immunol. 1977;59:334-8.
38. Ruiz B, Serrano P, Moreno C. IgE-Api m 4 is useful for identifying a particular phenotype of bee venom allergy. J Investig Allergol Clin Immunol. 2016;26:355-61.
39. Grunwald T, Bockisch B, Spillner E, Ring J, Bredehorst R, Ollert MW. Molecular cloning and expression in insect cells of honeybee venom allergen acid phosphatase (Api m 3). J Allergy Clin Immunol. 2006;117:848-54.
40. Blank S, Seismann H, Bockisch B, Braren I, Cifuentes L, McIntyre M, et al. Identification, recombinant expression, and characterization of the 100 kDa high molecular weight hymenoptera venom allergens Api m 5 and Ves v 3. J Immunol. 2010;184:5403-13.
41. Frick M, Fischer J, Helbling A, Ruëff F, Wieczorek D, Ollert M, et al. Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy. J Allergy Clin Immunol. 2016;138, 1663-71.e9.
42. Blank S, Seismann H, Michel Y, McIntyre M, Cifuentes L, Braren I, et al. Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts. Allergy. 2011;66:1322-9.
43. Kettner A, Hughes GJ, Frutiger S, Astori M, Roggero M, Spertini F, et al. Api m 6: a new bee venom allergen. J Allergy Clin
Immunol. 2001;107:914-20.
44. Michel Y, McIntyre M, Ginglinger H, Ollert M, Cifuentes L, Blank S, et al. The putative serine protease inhibitor Api m 6 from Apis mellifera venom: recombinant and structural evaluation. J Investig Allergol Clin Immunol. 2012;22:476-84.
45. Winningham KM, Fitch CD, Schmidt M, Hoffman DR. Hymenoptera venom protease allergens. J Allergy Clin Immunol. 2004;114:928-33.
46. Allergen nomenclature. WHO/IUIS Allergen Nomenclature Subcommittee (Internet). Available from: http://www.allergen.
org/viewallergen.php?aid=73
47. Blank S, Bantleon FI, McIntyre M, Ollert M, Spillner E. The major royal jelly proteins 8 and 9 (Api m 11) are glycosylated components of Apis mellifera venom with allergenic potential beyond carbohydrate-based reactivity. Clin Exp Allergy. 2012;42:976-85.
48. Blank S, Seismann H, McIntyre M, Ollert M, Wolf S, Bantleon FI, et al. Vitellogenins are new high molecular weight components and allergens (Api m 12 and Ves v 6) of Apis mellifera and Vespula vulgaris venom. PLoS One. 2013;8:e62009.
49. Treudler R, Simon JC. Overview of component resolved diagnostics. Curr Allergy Asthma Rep. 2013;13:110-7.
50. Incorvaia C, Mauro M. Can component-resolved diagnosis overturn the current knowledge on vespid allergy? Allergy.
2012;67:966.
51. Vos B, Köhler J, Müller S, Stretz E, Ruëff F, Jakob T. Spiking venom with rVes v 5 improves sensitivity of IgE detection in patients with allergy to Vespula venom. J Allergy Clin Immunol. 2013;131:1225-7, 1227.e1.
52. Moreno C, Barasona MJ, Serrano P, Justicia JL, Ruz JM, Guerra F. Alternating Polistes-Vespula venom immunotherapy: a therapeutic strategy to resolve a diagnostic deficiency. J Investig Allergol Clin Immunol. 2011;21:28-33.
53. Kolarich D, Leonard R, Hemmer W, Altmann F. The Nglycans of yellow jacket venom hyaluronidases and the protein sequence of its major isoform in Vespula vulgaris. FEBS J. 2005;272:5182-90.
54. Seismann H, Blank S, Braren I, Greunke K, Cifuentes L, Grunwald T, et al. Dissecting cross-reactivity in hymenoptera venom allergy by circumvention of alpha-1,3-core fucosylation. Mol Immunol. 2010;47:799-808.
55. King TP, Joslyn A, Kochoumian L. Antigenic cross-reactivity of venom proteins from hornets, wasps, and yellow jackets. J Allergy Clin Immunol. 1985;75:621-8.
56. Skov LK, Seppala U, Coen JJ, Crickmore N, King TP, et al. Structure of recombinant Ves v 2 at 2.0 Angstrom resolution: structural analysis of an allergenic hyaluronidase from wasp venom. Acta Crystallogr D: Biol Crystallogr. 2006;62: 595-604.
57. Sturm GJ, Jin C, Kranzelbinder B, Hemmer W, Sturm EM, Griesbacher A, et al. Inconsistent results of diagnostic tools hamper the differentiation between bee and vespid venom allergy. PLoS One. 2011;6:e20842.
58. Blank S, Neu C, Hasche D, Bantleon FI, Jakob T, Spillner E. Polistes species venom is devoid of carbohydratebased crossreactivity and allows interference-free diagnostics. J Allergy Clin Immunol. 2013;131:1239-42.
59. Caruso B, Bonadonna P, Severino MG, Manfredi M, Dama A, Schiappoli M, et al. Evaluation of the IgE cross-reactions among vespid venoms. A possible approach for the choice of immunotherapy. Allergy. 2007;62:561-4.
60. Pantera B, Hoffman DR, Carresi L, Cappugi G, Turillazzi S, Manao G, et al. Characterization of the major allergens purified from the venom of the paper wasp Polistes gallicus. Biochim Biophys Acta. 2003;1623:72-81.
61. Fernández J. Distribution of vespid species in Europe. Curr Opin in Allergy Clin Immunol. 2004;4:319-24.
62. Tibbetts EA, Skaldina O, Zhao V, Toth AL, Skaldin M, Beani L, et al. Geographic variation in the status signals of Polistes dominulus paper wasps. PLoS ONE. 2011;6:12. Article Number e28173.
63. Severino MG, Campi P, Macchia D, Manfredi M, Turillazzi S, Spadolini I, et al. European Polistes venom allergy. Allergy. 2006;61:860-3.
64. King TP, Kochoumian L, Joslyn A. Wasp venom proteins: phosholipase A1 and B. Arch Biochem Biophys. 1984;2030:1-12.
65. Sanchez F, Blanca M, Fernandez J, Miranda A, Terrados A, Torres MJ, et al. Comparative study between European and American species of Polistes using sera from European sensitized subjects. Clin Exp Allergy. 1995;25:281-7.
66. Galindo-Bonilla PA, Galán-Nieto A, Alfaya-Arias T, GarcíaRodríguez C, de la Roca-Pinzón F, Feo-Brito F. Componentresolved diagnosis in vespid venom-allergic individuals. Allergol Immunopathol (Madr). 2015;43:398-402.
67. Ebo DG, Van Vaerenbergh M, de Graaf DC, Bridts CH, De Clerck LS, Sabato V. In vitro diagnosis of Hymenoptera venom allergy and further development of component resolved diagnostics. Expert Rev Clin Immunol. 2014;10:375-84.
68. King TP, Lu G, Gonzalez M, Qian N, Soldatova L. Yellowjacket venom allergens, hyaluronidase and phospholipase: sequence similarity and antigenic cross-reactivity with their hornet and wasp homologs and possible implications for clinical allergy. J Allergy Clin Immunol. 1996;98:588-600.
69. de Groot H, de Graaf-in’t Veld C, van Wijk RG. Allergy to bumblebee venom. I. Occupational anaphylaxis to bumblebee venom: diagnosis and treatment. Allergy. 1995;50:581-4.
70. Cruz S, Vega A, Fernández S, Marquès L, Baltasar M, Alonso A, et al. Hymenoptera Committee; Spanish Society of Allergology and Clinical Immunology. Report from the Hymenoptera Committee of the Spanish Society of Allergology and Clinical Immunology: immunotherapy with bumblebee venom. J Investig Allergol Clin Immunol. 2012;22:377-8.
71. Bonifazi F, Jutel M, Biló BM, Birnbaum J, Muller U. EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy. 2005;60:1459-70.
72. Severino MG, Caruso B, Bonadonna P, Labardi D, Macchia D, Campi P, et al. Cross-reactivity between European hornet and yellow jacket venoms. Eur Ann Allergy Clin Immunol. 2010;42:141-5.
73. Wiese MD, Brown SG, Chataway TK, Davies NW, Milne RW, Aulfrey SJ, et al. Myrmecia pilosula (Jack Jumper) ant venom: identification of allergens and revised nomenclature. Allergy. 2007;62:437-43.
74. Brown SG, Wiese MD, van Eeden P, Stone SF, Chuter CL, Gunner J, et al. Ultrarush versus semirush initiation of insect venom immunotherapy: a randomized controlled trial. J Allergy Clin Immunol. 2012;130:162-8.
75. Hoffman DR. Ant venoms. Curr Opin Allergy Clin Immunol. 2010;10:342-6.
76. De Knop KJ, Bridts CH, Verweij MM, Hagendorens MM, De Clerck LS, Stevens WJ, et al. Component-resolved allergy diagnosis by microarray: potential, pitfalls, and prospects. Adv Clin Chem. 2010;50:87-101.
77. Gonzalez de Olano D, de la Hoz Caballer B, Nunez Lopez R, Sanchez Munoz L, Cuevas Agustin M, Dieguez MC, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy. 2007;37:1547-55.
78. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226-32.
79. Gonzalez-de-Olano D, Alvarez-Twose I, Vega A, Orfao A, Escribano L. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy. 2011;3:637-51.
80. Fricker M, Helbling A, Schwartz L, Muller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol. 1997;100:11-5.
81. Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy. 2003;33: 1216-20.
82. Esteban MI, Sánchez C, González ML, Santaolalla M, Núnez ˜ R, García A. Triptasa sérica en pacientes alérgicos a veneno de himenópteros. Alergol e Inmunol. 2004;19:1.
83. Alvarez-Twose I, Gonzalez de Olano D, Sanchez-Munoz L, Matito A, Esteban-Lopez MI, Vega A, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy
Clin Immunol. 2010;125, 1269-78e2.
84. Gonzalez-de-Olano D, Alvarez-Twose I, Morgado JM, Lopez MI, Castro AV, Diaz D, et al. Evaluation of basophil activation in mastocytosis with hymenoptera venom anaphylaxis. Cytometry B Clin Cytom. 2011;80:167-75.
85. Bonadonna P, Zanotti R, Melioli G, Antonini F, Romano I, Lenzi L, et al. The role of basophil activation test in special populations with mastocytosis and reactions to hymenoptera sting. Allergy. 2012;67:962-5.
86. Alvarez-Twose I, Zanotti R, González-de-Olano D, Bonadonna P, Vega A, Matito A, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol. 2014;133:520-8.
87. Alvarez-Twose I, Gonzalez-de-Olano D, Sanchez-Munoz L, Matito A, Jara-Acevedo M, Teodosio C, et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol. 2011;157:275-80.
88. de Olano G, Álvarez Towse I, Castells Guitart MC, Ferrer Puga M, Escribano Mora L. Síndromes de activación mastocitaria. In: Dávila González IJ, Jáuregui Presa I, Olaguibel Rivera JM, Zubeldia Ortuno˜ JM, editors. Tratado de Alergologia. Tomo IV. Madrid: Ergon; 2016. p. 1315.
89. Dhami S, Nurmatov U, Varga EM, Sturm G, Muraro A, Akdis CA, et al. Allergen immunotherapy for insect venom allergy: protocol for a systematic review. Clin Transl Allergy. 2016;6:6.
90. Alfaya Arias T, Soriano Gómis V, Soto Mera T, Vega Castro A, Vega Gutiérrez JM, Alonso Llamazares A, et al. Hymenoptera Allergy Committee of the SEAIC. Key issues in Hymenoptera venom allergy: an update. J Investig Allergol Clin Immunol. 2017;27:19-31.
2. Ollert M, Blank S. Anaphylaxis to insect venom allergens: role of molecular diagnosis. Curr Allergy Asthma Rep. 2015;15:26.
3. Elberink JN, Dubois AE. Quality of life in insect venom allergic patients. Curr Opin Allergy Clin Immunol. 2003;3:287-93.
4. Alfaya T, Vega A, Domínguez-Noche C, Ruíz B, Marques L, Sánchez-Morillas L. Longitudinal validation of the Spanish versión of the health-related quality of life questionnaire for hymenoptera venom allergy (HRQLHA). J Invest Allergol Clin Immunol. 2015;25:426-30.
5. Armisén M, Guspi R, Alfaya T, Crus S, Fernández S, DomínguezNoche C, et al. Cross-sectional validation of a quality of life questionnaire in Spanish for patients allergic to hymenoptera venom. J Investig Allergol Clin Immunol. 2015;25:176-82.
6. Sastre J. Molecular diagnosis in allergy. Clin Exp Allergy. 2010;40:1442-60.
7. Golden DB. Insect sting anaphylaxis. Immunol Allergy Clin North Am. 2007;27:261-72.
8. Müller U, Schmid-Grendelmeier P, Hausmann O, Helbling A. IgE to recombinant allergens Api m1, Ves v1 and Ves v5 distinguish double sensitization from crossreaction in venom allergy. Allergy. 2012;67:1069-73.
9. Pérez-Riverol A, Justo-Jacomini DL, Lima Zollner R, BrochettoBraga MR. Facing hymenoptera venom allergy: from natural to recombinant allergens. Toxins. 2015;7:2551-70.
10. Müller UR, Johansen N, Petersen AB, Fromberg-Nielsen J, Haeberli G. Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m1 and Ves v5. Allergy. 2009;64:543-8.
11. Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN. Diagnosis of hymenoptera venom allergy. Allergy. 2005;60: 1339-49.
12. Cifuentes L, Vosseler S, Blank S, Seismann H, Pennino D, Darsow U, et al. Identification of hymenoptera venom-allergic patients with negative specific IgE to venom extract by using recombinant allergens. J Allergy Clin Immunol. 2014;133: 909-10.
13. Marth K, Focke-Tejkl M, Lupinek C, Valenta R, Niederberger V. Allergen peptides, recombinant allergens and hypoallergens for allergen-specific immunotherapy. Curr Treat Options Allergy. 2014;1:91-106.
14. Monsalve RI, Vega A, Marques L, Miranda A, Fernández J, Soriano V, et al. Component-resolved diagnosis of vespid venom-allergic individuals: phospholipases and antigen 5s are necessary to identify Vespula or Polistes sensitization. Allergy. 2012;67:528-36.
15. Peiren N, Vanrobaeys F, de Graaf DC, Devreese B, Van Beeumen J, Jacobs FJ. The protein composition of honeybee venom reconsidered by a proteomic approach. Biochim Biophys Acta. 2005;1752:1-5.
16. Müller UR. Recombinant Hymenoptera venom allergens. Allergy. 2002;57:570-6.
17. Brown TC. Reactions to honeybee stings: an allergic prospective. Curr Opin Allergy Clin Immunol. 2013;13:365-71.
18. Spillner E, Blank S, Jakob T. Hymenoptera allergens: from venom to ‘‘venome’’. Front Immunol. 2014;5:77.
19. Sobotka AK, Franklin RM, Adkinson NF, Valentine M, Baer H, Lichtenstein LM. Allergy to insect stings. II. Phospholipase A: the major allergen in honeybee venom. J Allergy Clin Immunol. 1976;57:29-40.
20. Köhler J, Blank S, Müller S, Bantleon F, Frick M, Huss-Marp J, et al. Component resolution reveals additional major allergens in patients with honeybee venom allergy. J Allergy Clin Immunol. 2014;133:1383-9, 1389.e1-6.
21. Müller U. Insect sting allergy clinical: clinical picture, diagnosis and treatment. Stuttgart, New York: Gustav Fis.; 1990.
22. Kuchler K, Gmachl M, Sippl MJ, Kreil G. Analysis of the cDNA for phospholipase A2 from honeybee venom glands. The deduced amino acid sequence reveals homology to the corresponding vertebrate enzymes. Eur J Biochem. 1989;184:249-54.
23. Müller UR, Dudler T, Schneider T, Crameri R, Fischer H, Skrbic D, et al. Type I skin reactivity to native and recombinant phospholipase A2 from honeybee venom is similar. J Allergy Clin Immunol. 1995;96:395-402.
24. Dudler T, Chen WQ, Wang S, Schneider T, Annand RR, Dempcy RO, et al. High-level expression in Escherichia coli and rapid purification of enzymatically active honey bee venom phospholipase A2. Biochim Biophys Acta. 1992;1165:201-10.
25. Sturm GJ, Hemmer W, Hawranek T, Lang R, Ollert M, Spillner E, et al. Detection of IgE to recombinant Api m 1 and rVes v 5 is valuable but not sufficient to distinguish bee from wasp venom allergy. J Allergy Clin Immunol. 2011;128:247-8.
26. Koroˇsec P, Silar M, Zidarn M, Koˇsnik M. Reply: to PMID 22277204. J Allergy Clin Immunol. 2012;130:818-9.
27. Jakob T, Köhler J, Blank S, Magnusson U, Huss-Marp J, Spillner E, et al. Comparable IgE reactivity to natural and recombinant Api m 1 in cross-reactive carbohydrate determinant-negative patients with bee venom allergy. J Allergy Clin Immunol. 2012;130:276-8, author reply 278-9.
28. Koroˇsec P, Ziberna ˇ K, ˇSilar M, Deˇzman M, Celesnik ˇ Smodiˇs N, Rijavec M, et al. Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy. Clin Exp Allergy. 2015;45:1579-89.
29. Ruiz B, Serrano P, Verdú M, Moreno C. Sensitization to Api m 1, Api m 2, and Api m 4: association with safety of bee venom immunotherapy. Ann Allergy Asthma Immunol. 2015;114: 350-2.
30. Schrautzer C, Bokanovic D, Hemmer W, Lang R, Hawranek T, Schwarz I, et al. Sensitivity and specificity of Hymenoptera allergen components depend on the diagnostic assay employed. J Allergy Clin Immunol. 2016;137:1603-5.
31. Soldatova LN, Crameri R, Gmachl M, Kemeny DM, Schmidt M, Weber M, et al. Superior biologic activity of the recombinant bee venom allergen hyaluronidase expressed in baculovirus infected insect cells as compared with Escherichia coli. J Allergy Clin Immunol. 1998;101:691-8.
32. King TP, Spangfort MD. Structure and biology of stinging insect venom allergens. Int Arch Allergy Immunol. 2000;123: 99-106.
33. Jin C, Focke M, Leonard R, Jarisch R, Altmann F, Hemmer W. Reassessing the role of hyaluronidase in yellow jacket venom allergy. J Allergy Clin Immunol. 2010;125, 184-90.e1.
34. Kemeny DM, Dalton N, Lawrence AJ, Pearce FL, Vernon CA. The purification and characterisation of hyaluronidase from the venom of the honey bee, Apis mellifera. Eur J Biochem. 1984;139:217-23.
35. Gmachl M, Kreil G. Bee venom hyaluronidase is homologous to a membrane protein of mammalian sperm. Proc Natl Acad Sci U S A. 1993;90:3569-73.
36. Schröder E, Lübke K, Lehmann M, Beetz I. Haemolytic activity and action on the surface tension of aqueous solutions of synthetic melittins and their derivatives. Experientia. 1971;27:764-5.
37. Paull BR, Yunginger JW, Gleich GJ, Melittin: an allergen of honeybee venom. J Allergy Clin Immunol. 1977;59:334-8.
38. Ruiz B, Serrano P, Moreno C. IgE-Api m 4 is useful for identifying a particular phenotype of bee venom allergy. J Investig Allergol Clin Immunol. 2016;26:355-61.
39. Grunwald T, Bockisch B, Spillner E, Ring J, Bredehorst R, Ollert MW. Molecular cloning and expression in insect cells of honeybee venom allergen acid phosphatase (Api m 3). J Allergy Clin Immunol. 2006;117:848-54.
40. Blank S, Seismann H, Bockisch B, Braren I, Cifuentes L, McIntyre M, et al. Identification, recombinant expression, and characterization of the 100 kDa high molecular weight hymenoptera venom allergens Api m 5 and Ves v 3. J Immunol. 2010;184:5403-13.
41. Frick M, Fischer J, Helbling A, Ruëff F, Wieczorek D, Ollert M, et al. Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy. J Allergy Clin Immunol. 2016;138, 1663-71.e9.
42. Blank S, Seismann H, Michel Y, McIntyre M, Cifuentes L, Braren I, et al. Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts. Allergy. 2011;66:1322-9.
43. Kettner A, Hughes GJ, Frutiger S, Astori M, Roggero M, Spertini F, et al. Api m 6: a new bee venom allergen. J Allergy Clin
Immunol. 2001;107:914-20.
44. Michel Y, McIntyre M, Ginglinger H, Ollert M, Cifuentes L, Blank S, et al. The putative serine protease inhibitor Api m 6 from Apis mellifera venom: recombinant and structural evaluation. J Investig Allergol Clin Immunol. 2012;22:476-84.
45. Winningham KM, Fitch CD, Schmidt M, Hoffman DR. Hymenoptera venom protease allergens. J Allergy Clin Immunol. 2004;114:928-33.
46. Allergen nomenclature. WHO/IUIS Allergen Nomenclature Subcommittee (Internet). Available from: http://www.allergen.
org/viewallergen.php?aid=73
47. Blank S, Bantleon FI, McIntyre M, Ollert M, Spillner E. The major royal jelly proteins 8 and 9 (Api m 11) are glycosylated components of Apis mellifera venom with allergenic potential beyond carbohydrate-based reactivity. Clin Exp Allergy. 2012;42:976-85.
48. Blank S, Seismann H, McIntyre M, Ollert M, Wolf S, Bantleon FI, et al. Vitellogenins are new high molecular weight components and allergens (Api m 12 and Ves v 6) of Apis mellifera and Vespula vulgaris venom. PLoS One. 2013;8:e62009.
49. Treudler R, Simon JC. Overview of component resolved diagnostics. Curr Allergy Asthma Rep. 2013;13:110-7.
50. Incorvaia C, Mauro M. Can component-resolved diagnosis overturn the current knowledge on vespid allergy? Allergy.
2012;67:966.
51. Vos B, Köhler J, Müller S, Stretz E, Ruëff F, Jakob T. Spiking venom with rVes v 5 improves sensitivity of IgE detection in patients with allergy to Vespula venom. J Allergy Clin Immunol. 2013;131:1225-7, 1227.e1.
52. Moreno C, Barasona MJ, Serrano P, Justicia JL, Ruz JM, Guerra F. Alternating Polistes-Vespula venom immunotherapy: a therapeutic strategy to resolve a diagnostic deficiency. J Investig Allergol Clin Immunol. 2011;21:28-33.
53. Kolarich D, Leonard R, Hemmer W, Altmann F. The Nglycans of yellow jacket venom hyaluronidases and the protein sequence of its major isoform in Vespula vulgaris. FEBS J. 2005;272:5182-90.
54. Seismann H, Blank S, Braren I, Greunke K, Cifuentes L, Grunwald T, et al. Dissecting cross-reactivity in hymenoptera venom allergy by circumvention of alpha-1,3-core fucosylation. Mol Immunol. 2010;47:799-808.
55. King TP, Joslyn A, Kochoumian L. Antigenic cross-reactivity of venom proteins from hornets, wasps, and yellow jackets. J Allergy Clin Immunol. 1985;75:621-8.
56. Skov LK, Seppala U, Coen JJ, Crickmore N, King TP, et al. Structure of recombinant Ves v 2 at 2.0 Angstrom resolution: structural analysis of an allergenic hyaluronidase from wasp venom. Acta Crystallogr D: Biol Crystallogr. 2006;62: 595-604.
57. Sturm GJ, Jin C, Kranzelbinder B, Hemmer W, Sturm EM, Griesbacher A, et al. Inconsistent results of diagnostic tools hamper the differentiation between bee and vespid venom allergy. PLoS One. 2011;6:e20842.
58. Blank S, Neu C, Hasche D, Bantleon FI, Jakob T, Spillner E. Polistes species venom is devoid of carbohydratebased crossreactivity and allows interference-free diagnostics. J Allergy Clin Immunol. 2013;131:1239-42.
59. Caruso B, Bonadonna P, Severino MG, Manfredi M, Dama A, Schiappoli M, et al. Evaluation of the IgE cross-reactions among vespid venoms. A possible approach for the choice of immunotherapy. Allergy. 2007;62:561-4.
60. Pantera B, Hoffman DR, Carresi L, Cappugi G, Turillazzi S, Manao G, et al. Characterization of the major allergens purified from the venom of the paper wasp Polistes gallicus. Biochim Biophys Acta. 2003;1623:72-81.
61. Fernández J. Distribution of vespid species in Europe. Curr Opin in Allergy Clin Immunol. 2004;4:319-24.
62. Tibbetts EA, Skaldina O, Zhao V, Toth AL, Skaldin M, Beani L, et al. Geographic variation in the status signals of Polistes dominulus paper wasps. PLoS ONE. 2011;6:12. Article Number e28173.
63. Severino MG, Campi P, Macchia D, Manfredi M, Turillazzi S, Spadolini I, et al. European Polistes venom allergy. Allergy. 2006;61:860-3.
64. King TP, Kochoumian L, Joslyn A. Wasp venom proteins: phosholipase A1 and B. Arch Biochem Biophys. 1984;2030:1-12.
65. Sanchez F, Blanca M, Fernandez J, Miranda A, Terrados A, Torres MJ, et al. Comparative study between European and American species of Polistes using sera from European sensitized subjects. Clin Exp Allergy. 1995;25:281-7.
66. Galindo-Bonilla PA, Galán-Nieto A, Alfaya-Arias T, GarcíaRodríguez C, de la Roca-Pinzón F, Feo-Brito F. Componentresolved diagnosis in vespid venom-allergic individuals. Allergol Immunopathol (Madr). 2015;43:398-402.
67. Ebo DG, Van Vaerenbergh M, de Graaf DC, Bridts CH, De Clerck LS, Sabato V. In vitro diagnosis of Hymenoptera venom allergy and further development of component resolved diagnostics. Expert Rev Clin Immunol. 2014;10:375-84.
68. King TP, Lu G, Gonzalez M, Qian N, Soldatova L. Yellowjacket venom allergens, hyaluronidase and phospholipase: sequence similarity and antigenic cross-reactivity with their hornet and wasp homologs and possible implications for clinical allergy. J Allergy Clin Immunol. 1996;98:588-600.
69. de Groot H, de Graaf-in’t Veld C, van Wijk RG. Allergy to bumblebee venom. I. Occupational anaphylaxis to bumblebee venom: diagnosis and treatment. Allergy. 1995;50:581-4.
70. Cruz S, Vega A, Fernández S, Marquès L, Baltasar M, Alonso A, et al. Hymenoptera Committee; Spanish Society of Allergology and Clinical Immunology. Report from the Hymenoptera Committee of the Spanish Society of Allergology and Clinical Immunology: immunotherapy with bumblebee venom. J Investig Allergol Clin Immunol. 2012;22:377-8.
71. Bonifazi F, Jutel M, Biló BM, Birnbaum J, Muller U. EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy. 2005;60:1459-70.
72. Severino MG, Caruso B, Bonadonna P, Labardi D, Macchia D, Campi P, et al. Cross-reactivity between European hornet and yellow jacket venoms. Eur Ann Allergy Clin Immunol. 2010;42:141-5.
73. Wiese MD, Brown SG, Chataway TK, Davies NW, Milne RW, Aulfrey SJ, et al. Myrmecia pilosula (Jack Jumper) ant venom: identification of allergens and revised nomenclature. Allergy. 2007;62:437-43.
74. Brown SG, Wiese MD, van Eeden P, Stone SF, Chuter CL, Gunner J, et al. Ultrarush versus semirush initiation of insect venom immunotherapy: a randomized controlled trial. J Allergy Clin Immunol. 2012;130:162-8.
75. Hoffman DR. Ant venoms. Curr Opin Allergy Clin Immunol. 2010;10:342-6.
76. De Knop KJ, Bridts CH, Verweij MM, Hagendorens MM, De Clerck LS, Stevens WJ, et al. Component-resolved allergy diagnosis by microarray: potential, pitfalls, and prospects. Adv Clin Chem. 2010;50:87-101.
77. Gonzalez de Olano D, de la Hoz Caballer B, Nunez Lopez R, Sanchez Munoz L, Cuevas Agustin M, Dieguez MC, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy. 2007;37:1547-55.
78. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226-32.
79. Gonzalez-de-Olano D, Alvarez-Twose I, Vega A, Orfao A, Escribano L. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy. 2011;3:637-51.
80. Fricker M, Helbling A, Schwartz L, Muller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol. 1997;100:11-5.
81. Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy. 2003;33: 1216-20.
82. Esteban MI, Sánchez C, González ML, Santaolalla M, Núnez ˜ R, García A. Triptasa sérica en pacientes alérgicos a veneno de himenópteros. Alergol e Inmunol. 2004;19:1.
83. Alvarez-Twose I, Gonzalez de Olano D, Sanchez-Munoz L, Matito A, Esteban-Lopez MI, Vega A, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy
Clin Immunol. 2010;125, 1269-78e2.
84. Gonzalez-de-Olano D, Alvarez-Twose I, Morgado JM, Lopez MI, Castro AV, Diaz D, et al. Evaluation of basophil activation in mastocytosis with hymenoptera venom anaphylaxis. Cytometry B Clin Cytom. 2011;80:167-75.
85. Bonadonna P, Zanotti R, Melioli G, Antonini F, Romano I, Lenzi L, et al. The role of basophil activation test in special populations with mastocytosis and reactions to hymenoptera sting. Allergy. 2012;67:962-5.
86. Alvarez-Twose I, Zanotti R, González-de-Olano D, Bonadonna P, Vega A, Matito A, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol. 2014;133:520-8.
87. Alvarez-Twose I, Gonzalez-de-Olano D, Sanchez-Munoz L, Matito A, Jara-Acevedo M, Teodosio C, et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol. 2011;157:275-80.
88. de Olano G, Álvarez Towse I, Castells Guitart MC, Ferrer Puga M, Escribano Mora L. Síndromes de activación mastocitaria. In: Dávila González IJ, Jáuregui Presa I, Olaguibel Rivera JM, Zubeldia Ortuno˜ JM, editors. Tratado de Alergologia. Tomo IV. Madrid: Ergon; 2016. p. 1315.
89. Dhami S, Nurmatov U, Varga EM, Sturm G, Muraro A, Akdis CA, et al. Allergen immunotherapy for insect venom allergy: protocol for a systematic review. Clin Transl Allergy. 2016;6:6.
90. Alfaya Arias T, Soriano Gómis V, Soto Mera T, Vega Castro A, Vega Gutiérrez JM, Alonso Llamazares A, et al. Hymenoptera Allergy Committee of the SEAIC. Key issues in Hymenoptera venom allergy: an update. J Investig Allergol Clin Immunol. 2017;27:19-31.
Article Sidebar
Published
Jun 15, 2018
Article Details
How to Cite
Antolín-Amérigo, D., Ruiz-León, B., Boni, E., Alfaya-Arias, T., Álvarez-Mon, M., Barbarroja-Escudero , J. ., González-de-Olano, D., Moreno-Aguilar, C., Rodríguez-Rodríguez, M., Sánchez-González, M., Sánchez-Morillas, L., & Vega-Castro, A. (2018). Component-resolved diagnosis in hymenoptera allergy. Allergologia Et Immunopathologia, 46(3), 253-262. https://all-imm.com/index.php/aei/article/view/413
Issue
Section
Review Article
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Antolín-Amérigo, D., Ruiz-León, B., Boni, E., Alfaya-Arias, T., Álvarez-Mon, M., Barbarroja-Escudero , J. ., González-de-Olano, D., Moreno-Aguilar, C., Rodríguez-Rodríguez, M., Sánchez-González, M., Sánchez-Morillas, L., & Vega-Castro, A. (2018). Component-resolved diagnosis in hymenoptera allergy. Allergologia Et Immunopathologia, 46(3), 253-262. https://all-imm.com/index.php/aei/article/view/413